GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials.

ABSTRACT:

Background

The main objective of phase I cancer clinical trials is to identify the maximum tolerated dose, usually defined as the highest dose associated with an acceptable level of severe toxicity during the first cycle of treatment. Several dose-escalation designs based on mathematical modeling of the dose-toxicity relationship have been developed. The main ones are: the continual reassessment method (CRM), the escalation with overdose control (EWOC) method and, for late-onset and cumulative toxicities, the time-to-event continual reassessment method (TITE-CRM) and the time-to-event escalation with overdose control (TITE-EWOC) methods. The objective of this work was to perform a user-friendly R package that combines the latter model-guided adaptive designs.

Results

GUIP1 i

SUBMITTER: Dinart D 

PROVIDER: S-EPMC7469913 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature